CIK 0001160308
- Non-accelerated filer
- Smaller reporting company
Savara Inc
Sign in to watch- Ticker
- SVRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841318182
- Phone
- +51 285113796
- Business address
- 6836 BEE CAVE ROAD, BUILDING 3, SUITE 201, AUSTIN, TX, 78746
- Former names
- Mast Therapeutics, Inc., ADVENTRX PHARMACEUTICALS INC, BIOKEYS PHARMACEUTICALS INC
- 4 Open-market buy Director bought 50,000 shares at an average $1.28 ($64,035)
- 4 Open-market buy CHIEF FINANCIAL OFFICER bought 4,000 shares at $1.14 ($4,569)
- 4 Open-market buy Director bought 40,000 shares at an average $1.11 ($44,485)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award CHIEF EXECUTIVE OFFICER acquired 400,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 125,000 shares (grant or award)
- 4 Exercise or conversion Director acquired 728 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Grant or award CHIEF MEDICAL OFFICER acquired 125,000 shares (grant or award)
- 4 Open-market buy Director bought 35,000 shares at $1.04 ($36,365)
- 4 Open-market buy Director bought 25,000 shares at an average $1.05 ($26,214)
- 4 Open-market buy CHIEF MEDICAL OFFICER bought 25,000 shares at $1.05 ($26,250)
- 4 Exercise or conversion Director acquired 1,172 shares (option exercise)
- 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 6,500 shares at $1.06 ($6,889)
- 4 Open-market buy Director bought 25,000 shares at an average $1.09 ($27,128)
- 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 10,000 shares at $1.10 ($10,954)
- 4 Open-market buy Director bought 25,000 shares at an average $1.09 ($27,157)
Page 6 of 22 · 436 filings